Procter & Gamble Health Peer Comparison

NSE: PGHL | BSE: 500126

₹5,200.00

₹51.00 (0.99%)

As on 16-Oct-2026IST

Market cap

₹8,641 Cr

Revenue (TTM)

₹1,433 Cr

P/E Ratio

24.2

P/B Ratio

Div. Yield

3.9 %

Edit

	Procter & Gamble Health	Astrazeneca Pharma	Bliss GVS Pharma	Caplin Point Lab	CORONA Remedies	Eris Lifesciences	Pfizer	Shilpa Medicare	Strides Pharma	Supriya Lifescience
Market cap (₹ Cr)	8,641	14,915	7,009	17,484	12,234	15,832	17,475	18,336	9,624	7,129
Revenue (₹ Cr)	1,433	2,432	1,005	2,287	1,479	3,230	2,570	1,682	5,004	873
Net Profit (₹ Cr)	356.88	169.62	141.74	678.07	198.55	666.92	735.15	273.51	635.34	198.37
Net Margin (%)	24.61	6.90	13.31	28.10	13.32	20.60	26.88	16.19	12.33	22.44
RoE (%)	58.24	20.76	11.84	19.73	30.33	18.75	19.16	11.15	19.77	17.43
Price to Earnings	24.21	87.93	51.46	26.28	61.47	24.59	23.77	61.67	15.69	35.94
Price-To-Book	14.04	16.50	5.68	4.76	15.16	3.93	3.97	6.83	2.94	5.84

Income Statement (₹ Cr)

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	1,432.94	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	1,450.13	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	967.02	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	465.92	478.55	796.58	941.63	1,139.61
Depreciation	24.17	126.01	78.10	57.58	281.06
EBIT	441.75	352.55	718.48	884.05	858.55
Interest	0.57	52.11	0.88	7.69	190.64
Other Income	17.19	7.37	125.96	165.62	7.45
Exceptional Items	31.80	12.16	0.00	-49.16	-17.24
Profit before Tax	490.17	319.96	843.56	992.82	658.12
Provision for Tax	133.29	46.45	165.49	257.67	-8.80
Profit after Tax	356.88	273.51	678.07	735.15	666.92

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	524.55	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	61.87	266.35	28.74	91.50	1,392.75
Current Liabilities	254.93	848.06	385.94	627.48	2,077.10
Total Liabilities	841.35	3,705.61	4,037.51	4,921.88	7,246.72

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	150.47	2,525.44	1,291.22	770.28	5,617.77
Current Assets	556.26	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	841.35	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	0.00	657.97	0.57	2.50	2,309.68
Net Current Assets	301.33	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	174.73	160.01	17.53	370.49	51.57

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	337.79	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	1.26	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-343.92	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-4.87	29.88	-105.52	-392.41	-145.00

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	84.86	11.43	24.97	23.39	14.47
ROE (%)	58.24	11.15	19.73	19.16	18.75
ROA (%)	43.64	7.80	18.69	14.95	9.26
EBIT Margin (%)	30.83	20.95	31.41	34.40	26.58
Net Margin (%)	24.61	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	12.57	27.91	15.01	10.69	9.59
EBIT Growth (%)	14.27	58.32	18.45	24.14	16.84
Net Profit Growth (%)	18.73	149.56	19.61	-9.09	62.68
EPS Growth (%)	10.85	-3.57	17.73	14.40	67.41
Book Value Growth (%)	-2.37	9.67	26.75	-0.34	36.71

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	25.93	65.42	26.28	22.65	23.97
Price / Book Value	14.04	6.83	4.76	3.97	3.93
Dividend Yield (%)	3.94	0.06	0.35	1.96	0.00
EV/EBITDA	18.15	39.60	20.69	15.26	15.86
Market Cap (₹ Cr)	7,964.89	6,819.66	11,439.22	21,592.90	17,980.08

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.24
Short term debt to equity ratio	--	0.16	0.00	0.00	0.12
Current Ratio	2.18	1.31	6.70	6.06	0.74
Quick Ratio	1.65	0.88	5.59	5.31	0.53
Interest Coverage	860.95	7.14	959.59	130.11	4.45

	Procter & Gamble Health	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	11.46	30.84	36.10	7.07	21.07
Asset Turnover	1.75	0.48	0.63	0.52	0.45
Receivable days	36.06	113.81	121.68	26.06	63.88
Inventory Days	28.65	84.76	63.83	65.95	43.27
Payable days	181.85	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-117.14	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.